After dimerization with HIF-1β, HIF-1α binds to a promoter consensus sequence called hypoxia-responsive element (HRE), and controls the expression of several target genes involved in many aspects of cancer progression, including angiogenesis (e.g., vascular endothelial growth factor - VEGF), metabolic adaptation (e.g., Glut1), chemoresistance (e.g., MDR1), apoptosis resistance (e.g., Bcl2), invasion and metastasis (e.g., c-Met) [8]. The gene discussed is HIF1A; the disease is cancer.